• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Altamira Therapeutics Ltd. - Common Shares (NQ:CYTO)

0.3001 UNCHANGED
Last Price Updated: 3:55 PM EST, Dec 19, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Altamira Therapeutics Ltd. - Common Shares

< Previous 1 2 3 4 Next >
News headline image
Altamira Therapeutics Announces Transition from NASDAQ to OTC Markets
December 20, 2024
From Altamira Therapeutics Ltd
Via GlobeNewswire
News headline image
Altamira Therapeutics Provides Update on Nasdaq Listing
October 04, 2024
From Altamira Therapeutics Ltd
Via GlobeNewswire
News headline image
Altamira Therapeutics Announces Extended ISO 13485 Quality Management System Certification for Bentrio Nasal Spray
September 27, 2024
From Altamira Therapeutics Ltd
Via GlobeNewswire
News headline image
Altamira Therapeutics Provides Business Update and First Half 2024 Financial Results
September 24, 2024
From Altamira Therapeutics Ltd
Via GlobeNewswire
News headline image
Altamira Therapeutics to Host First Half 2024 Financial Results and Business Update Call on September 24, 2024
September 20, 2024
From Altamira Therapeutics Ltd
Via GlobeNewswire
News headline image
Altamira Therapeutics Announces Closing of up to $12.0 Million Public Offering
September 19, 2024
From Altamira Therapeutics Ltd
Via GlobeNewswire
News headline image
Altamira Therapeutics Announces Pricing of up to $12.0 Million Public Offering
September 17, 2024
From Altamira Therapeutics Ltd
Via GlobeNewswire
News headline image
Altamira Therapeutics Announces Expansion of Bentrio License and Distribution Agreement with Nuance Pharma in East and South East Asia
September 16, 2024
From Altamira Therapeutics Ltd
Via GlobeNewswire
News headline image
Altamira Therapeutics to Present at H.C. Wainwright 26th Annual Global Investment Conference September 9-11
September 03, 2024
From Altamira Therapeutics Ltd
Via GlobeNewswire
News headline image
Altamira Therapeutics Announces Extension of Bentrio Distribution Agreement with Pharma Nordic to Include Sweden and Denmark
August 23, 2024
From Altamira Therapeutics Ltd
Via GlobeNewswire
News headline image
Altamira Therapeutics Announces Confirmed Suitability of Bentrio for Athletes as Comprehensive Testing Shows Absence of Prohibited Substances
August 16, 2024
From Altamira Therapeutics Ltd
Via GlobeNewswire
News headline image
Altamira Therapeutics Announces Significant Enhancement of Immune Checkpoint Inhibition Therapy in Combination with Zbtb46 mRNA Delivered with SemaPhore Nanoparticles in Animal Tumor Models
August 12, 2024
From Altamira Therapeutics Ltd
Via GlobeNewswire
News headline image
Altamira Therapeutics Announces Publication of Preclinical Data Showing Successful Treatment of Abdominal Aortic Aneurysm with SOD2 mRNA Delivered by SemaPhore Nanoparticles
July 19, 2024
From Altamira Therapeutics Ltd
Via GlobeNewswire
News headline image
Altamira Therapeutics Highlights Newly Published Review Article Supporting Use of Betahistine in Vertigo Management
June 20, 2024
From Altamira Therapeutics Ltd
Via GlobeNewswire
News headline image
Altamira Therapeutics Provides Business Update
May 28, 2024
From Altamira Therapeutics Ltd
Via GlobeNewswire
News headline image
Biotechs Zero in on New Pancreatic Therapies as Global Pancreatic Cancer Market Expected Reach to $7.4 Billion By 2032
May 24, 2024
EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:RENB),(NASDAQ:CYTO),(NYSE:PFE),(NYSE:ABBV) EQNX::TICKER_END 
Via FinancialNewsMedia
Topics Death
News headline image
Altamira Therapeutics Announces Dissemination of Positive Results from Bentrio Trial in Seasonal Allergic Rhinitis Through Social Media Channels of Top Allergy Journal
May 23, 2024
From Altamira Therapeutics Ltd
Via GlobeNewswire
News headline image
Biotechs Zero in on New Pancreatic Therapies as Global Pancreatic Cancer Market Expected Reach to $7.4 Billion By 2032
May 24, 2024
From FN Media Group LLC
Via GlobeNewswire
News headline image
Altamira Therapeutics Announces Filing of Provisional Patent Application for OligoPhore Nanoparticles with siRNA Targeting p65 Protein in Treatment of Cancer and Inflammation
May 01, 2024
From Altamira Therapeutics Ltd
Via GlobeNewswire
News headline image
Altamira Therapeutics Announces Publication of Positive Results from Bentrio Trial in Seasonal Allergic Rhinitis in Top Peer Reviewed Journal
April 24, 2024
From Altamira Therapeutics Ltd
Via GlobeNewswire
News headline image
Altamira Therapeutics Provides Business Update, Reports Full Year 2023 Financial Results
April 10, 2024
From Altamira Therapeutics Ltd
Via GlobeNewswire
News headline image
Altamira Therapeutics to Host Full Year 2023 Financial Results and Business Update Call on April 10, 2024
April 04, 2024
From Altamira Therapeutics Ltd
Via GlobeNewswire
News headline image
Altamira Therapeutics Announces Collaboration with Univercells Group on Nanoparticle-Delivered mRNA Vaccines
March 25, 2024
From Altamira Therapeutics Ltd
Via GlobeNewswire
News headline image
Altamira Therapeutics’ Peptide-Based Delivery Platform Shown to Enhance Potency of Commonly Used Gene Delivery Method as Published in Peer-Reviewed Journal
February 07, 2024
From Altamira Therapeutics Ltd
Via GlobeNewswire
News headline image
Altamira Therapeutics Files Second Provisional Patent Application for OligoPhore Nanoparticles Targeting Different KRAS Mutations in Cancer Treatment
January 24, 2024
From Altamira Therapeutics Ltd
Via GlobeNewswire
News headline image
Altamira Therapeutics to Present at 3rd Annual mRNA-Based Therapeutics Summit
January 08, 2024
From Altamira Therapeutics Ltd
Via GlobeNewswire
News headline image
Altamira Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement
December 29, 2023
From Altamira Therapeutics Ltd
Via GlobeNewswire
News headline image
Altamira Therapeutics Provides Investor and Business Update
December 11, 2023
From Altamira Therapeutics Ltd
Via GlobeNewswire
News headline image
Altamira Therapeutics to Host Investor & Business Update Call on December 11th
December 05, 2023
From Altamira Therapeutics Ltd
Via GlobeNewswire
News headline image
Altamira Therapeutics Regains Compliance with Nasdaq Minimum Stockholders' Equity Requirement
November 29, 2023
From Altamira Therapeutics Ltd
Via GlobeNewswire
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap